Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker. View Source Jaimy Lee MarketWatch.com –…
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker. View Source Jaimy Lee MarketWatch.com –…
A large institutional options fund may have contributed to some of the recent volatility in the S&P 500. View Source Gordon Gottsegen MarketWatch.com – Top…
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals View Source Jaimy…
McCormick’s stock surges amid talks to combine with Unilever’s foods business, but there’s no mention of the deal in the earnings report. View Source Tomi…
Several factors are conspiring to drive interest rate structurally higher, to the detriment of private credit. View Source Jules Rimmer MarketWatch.com – Top Stories March…
View Source Most popular articles March 31, 2026 4:35 am
View Source Most popular articles March 31, 2026 4:30 am
View Source Most popular articles March 31, 2026 4:30 am
Strategists lowered their rating on global stocks while saying investors should hold onto more cash and U.S. Treasury securities. View Source Steve Goldstein MarketWatch.com –…
“We have no experience with Treasurys .” View Source Quentin Fottrell MarketWatch.com – Top Stories March 31, 2026 3:55 am